1. Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention
    Naomi F. Lange et al, 2021, Journal of Hepatology CrossRef
  2. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial
    I. Walter et al, 2017, Medical Oncology CrossRef
  3. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis
    Daniel Sepulveda-Crespo et al, 2021, Drugs CrossRef
  4. Diabetes medications and risk of HCC
    Maria Corina Plaz Torres et al, 2022, Hepatology CrossRef
  5. Hepatitis C and insulin action: An intimate relationship
    Hilla Knobler, 2016, World Journal of Hepatology CrossRef
  6. Activation of peroxisome proliferator-activated receptor-gamma inhibits tumor growth by negatively regulating nuclear factor-κB activation in patients with hepatocellular carcinoma
    Hiroyuki Nojima et al, 2016, Journal of Hepato-Biliary-Pancreatic Sciences CrossRef
  7. Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
    Jerry R. Colca et al, 2017, Hepatology Communications CrossRef
  8. Diabetes and Hepatitis C: A Two-Way Association
    Sara Salehi Hammerstad et al, 2015, Frontiers in Endocrinology CrossRef
  9. Wheat-bran autolytic peptides containing a branched-chain amino acid attenuate non-alcoholic steatohepatitis via the suppression of oxidative stress and the upregulation of AMPK/ACC in high-fat diet-fed mice
    Takumi Kawaguchi et al, 2017, International Journal of Molecular Medicine CrossRef
  10. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review
    Anne-Claire Desbois et al, 2017, World Journal of Gastroenterology CrossRef
  11. Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?
    Rasha Youssef Hagag et al, 2022, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy CrossRef
  12. Hepatitis C–Associated Diabetes Mellitus
    Ines Bilić-Ćurčić et al, 2017, Update on Hepatitis C CrossRef
  13. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
    Waihong Chung et al, 2020, World Journal of Hepatology CrossRef
  14. Mitochondrial Dysfunction in the Transition from NASH to HCC
    Mélissa Léveillé et al, 2019, Metabolites CrossRef